Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Digital health tools

Topic: Risk, prevention and care in population studies

Background QEEG could provide physiological biomarkers for changes over time in Parkinson's disease (PD) cognitive decline if they track with longitudinal neuropsychological performance. Objective Our aim was to correlate longitudinal changes in frequency domain quantitative electroencephalography (QEEG) measures with change in neuropsychological performance testing in PD. Methods 71 PD subjects, not demented at baseline, were studied from the Arizona Study of Aging and Neurodegenerative Disorders cohort. Baseline and follow-up digital EEG from PD subjects were analyzed for QEEG measures of background rhythm frequency and global relative power in delta (2.5-4 Hz), theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) bands. Baseline and subsequent evaluation included Mini Mental Status Examination and five other neuropsychological tests that load on cognitive domains known to decline in PD. Pearson coefficient was used to assess correlations. Multiple linear regression modeling was used to assess the effect of variable combinations of QEEG and other measures, including age and PD duration. Results Changes in delta bandpower showed the highest and most consistent pattern of correlations with longitudinal changes in neuropsychological testing. The highest correlation was between delta bandpower increase and decline in the Rey Auditory-Verbal Learning Test (-0.59:p Conclusions 1) Longitudinal change in the QEEG frequency domain measure of delta bandpower correlated best with longitudinal neuropsychological performance change in PD; 2) These results constitute preliminary evidence that delta bandpower may be a suitable biomarker for evaluating PD cognitive deterioration longitudinally.

Key findings

Why it matters

This longitudinal study of 71 people with Parkinson's disease found that changes in delta bandpower on EEG correlated with longitudinal changes in neuropsychological testing. It is about a potential physiological biomarker and does not test any treatment, cure or prevention.

Study details

How this study scored 48/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 0 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 48 of 100.48 of 100 points earned52 not earned

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Parkinson's disease)
Journal's citation record 1 / 4 Journal of Parkinson s Disease: journal h-index 97 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 93 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.2 citations a year over 13 year(s) since 2015
Impact for its field and year 3 / 6 Cited 4.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 2 / 4 Cited 24 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Charles H. Adler: h-index 93 (OpenAlex, whole career)
Institution's track record 0 / 3 Mayo Clinic in Arizona: institution h-index 590 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 25420672)
Free to read 0 / 2 Behind a paywall — scores zero
Total 48 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Caviness, J. N., Hentz, J. G., Belden, C. M., Shill, H. A., Driver-Dunckley, E. D., Sabbagh, M. N., et al. (2015). Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease. Journal of Parkinson's disease. https://doi.org/10.3233/jpd-140480

Vancouver

Caviness JN, Hentz JG, Belden CM, Shill HA, Driver-Dunckley ED, Sabbagh MN, et al. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease. Journal of Parkinson's disease. 2015. doi:10.3233/jpd-140480. PMID: 25420672.

BibTeX

@article{caviness2015-25420672,
  author  = {Caviness, J. N. and Hentz, J. G. and Belden, C. M. and Shill, H. A. and Driver-Dunckley, E. D. and Sabbagh, M. N. and Powell, J. J. and Adler, C. H.},
  title   = {{Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease}},
  journal = {Journal of Parkinson's disease},
  year    = {2015},
  doi     = {10.3233/jpd-140480},
  pmid    = {25420672},
  url     = {https://doi.org/10.3233/jpd-140480}
}

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Digital health tools

Similar studies

More on Digital health tools

See all studies in Digital health tools →